Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status

Rucaparib: A Review in Ovarian Cancer

(2019) Matt Shirley   Targeted Oncology

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers

(2019) Man Keung et al.   Journal of Clinical Medicine

Novel insights into PARPs in gene expression: regulation of RNA metabolism

(2019) Yueshuang Ke et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Evidence to date: talazoparib in the treatment of breast cancer

(2019) Pedro Exman et al.   OncoTargets and Therapy

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis

(2018) Haixia Chen et al.   Frontiers in Pharmacology

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

(2018) Todd A. Hopkins et al.   MOLECULAR CANCER RESEARCH

Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer

(2017) Kalnisha Naidoo et al.   MOLECULAR CANCER THERAPEUTICS

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

(2017) Helen Davies et al.   NATURE MEDICINE

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

(2016) Benjamin H. Lok et al.   CLINICAL CANCER RESEARCH

Proteogenomics connects somatic mutations to signalling in breast cancer

(2016) Philipp Mertins et al.   NATURE

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

(2016) Y. Pommier et al.   Science Translational Medicine

Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells

(2015) Józefa Węsierska-Gądek et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

(2015) T. A. Hopkins et al.   MOLECULAR CANCER RESEARCH

The Global Burden of Cancer 2013

(2015) Christina Fitzmaurice et al.   JAMA Oncology

Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors

(2014) Poorval M. Joshi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

(2013) I. Bajrami et al.   CANCER RESEARCH

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

(2013) Julio Morales et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN

(2013) Yanyuan Wu et al.   PLoS One

Identification of Pim Kinases as Novel Targets for PJ34 with Confounding Effects in PARP Biology

(2012) Albert A. Antolín et al.   ACS Chemical Biology

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

(2012) T. Popova et al.   CANCER RESEARCH

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

(2012) Sohrab P. Shah et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1

(2012) M.-F. Langelier et al.   SCIENCE

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents

(2012) Nicolai J. Birkbak et al.   Cancer Discovery

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes

(2011) D. Blazek et al.   GENES & DEVELOPMENT

Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2

(2010) Nancie Petrucelli et al.   GENETICS IN MEDICINE

Histological types of breast cancer: How special are they?

(2010) Britta Weigelt et al.   Molecular Oncology

Resistance to Trastuzumab in Breast Cancer

(2009) P. R. Pohlmann et al.   CLINICAL CANCER RESEARCH

Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation

(2008) W Lee Kraus   CURRENT OPINION IN CELL BIOLOGY